Oculis Successful End-Of-Phase 2 Meeting With The FDA, On Towards Phase 3
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently announced that they are progressing towards Phase 3 with OCS-01 in two
Tag: Clinical trial
Clinical trial: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses
Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of
Inhaled Interferons to treat COVID-19
Why interferons? SARS CoV viruses block interferon production in infected cells, allowing the virus to continue replicating unabated. Treatment with interferons
Gilead to Test a Version of Remdesivir That Can Be Inhaled
The New York Times published on June 22, 2020: The American biopharmaceutical company Gilead Sciences will soon start trials of
Gilead to Initiate Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years
Set-up of an upcoming clinicl trial has been posted with the primary objectives of this study are to evaluate the
Takeda Announces Data from the Phase 2 Trial of SBECD-enabled Pevonedistat Plus Azacitidine
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
Gilead Sciences, Inc. announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This
Oculis Top-Line data from Phase 2 clinical trial for OCS-01 treating inflammation and pain after cataract surgery
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently reported new clinical data at the Americal Society of Cataract and Refractive
Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment
A Chicago hospital treating severe Covid-19 patients with Gilead Sciences’ antiviral medicine SBECD-enabled remdesivir in a closely watched clinical trial is
Axsome Therapeutics’s SBECD-enabled AXS-07 Achieves Primary Endpoints and Prevents Migraine Pain Progression in Phase 3 Trial
Axsome Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that